argenx (ARGX) Stock Price, Quote, News & History | Benzinga

argenx SE (ARGX) Stock Price, Quote, News & History

ARGXNASDAQ

Trade with Public

Trade with Public

$1032.86

39.874.02%

At close: Aug 19, 5:00 PM EST

$1032.86

N/A

After Hours: 4:00 PM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$1.02K

Close

$1.03K

Volume / Avg.

390.89K / 332.76K

Day Range

$1.01K - $1.04K

52 Wk Range

650.01 - 1.01K

Market Cap

$64.62B

P/E Ratio

37.83

Dividend Yield

-

Exchange

NASDAQ

RSI

73

Short Interest

2.13%

Days to Cover

4.71

Recent argenx SE News

Snowflake To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. HC Wainwright & Co raised the price target for argenx SE - ADR (NASDAQ: ARGX) from $940 to $1,202. Goldman Sachs boosted PBF Energy Inc (NYSE: PBF) price target from $71 to $81. B of A Securities increased price target for Americold Realty Trust Inc (NYSE: COLD) from $15 to $16.

Avi Kapoor

These Analysts Boost Their Forecasts On Argenx

Argenx SE (NASDAQ:ARGX) reports positive Phase 3 results for VYVGART Hytrulo in autoimmune myositis. Analysts raise price targets on ARGX stock.

Avi Kapoor

Gold Gains 1%; US Home-Builder Sentiment Edges Higher In August

US stocks mixed, S&P 500 drops 0.2%. Dow down 0.34%, NASDAQ up 0.04%. Industrials up 0.2%, consumer staples down 1%. NY Fed's Empire State Index at 20.6.

Avi Kapoor

H World Group Posts Upbeat Q2 Results, Joins Almonty Industries, Diana Shipping And Other Big Stocks Moving Higher On Monday

H World Group (HTHT) beats earnings and raises sales guidance, shares jump 8.1%. Other big gainers include ANGX, ARGX, and MESO.

Avi Kapoor

Argenx’s Next Blockbuster? Stock Jumps 12% After Phase 3 Myositis Trial Hits Key Goal

Argenx stock surges 12% as VYVGART Hytrulo hits Phase 3 ALKIVIA endpoint in autoimmune myositis, showing strong 52-week clinical efficacy.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

974.19M

Investing Cash Flow (TTM)

264.01M

Financing Cash Flow (TTM)

264.01M

Free Cash Flow (TTM)

903.51M

Capital Expenditure (TTM)

-70.68M

Net Change in Cash (TTM)

1.50B

Analyst Trends and Forecast

1

Apr

3

May

5

Jun

7

1

Jul

7

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.1

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$57.90B

PE Ratio (TTM)

37.83

PE Ratio (FWD)

35.34

PEG Ratio (TTM)

1.52

PS Ratio (TTM)

12.42

PB Ratio (TTM)

7.38

Earnings Yield % (TTM)

2.64%

Earnings Yield % (FWD)

2.83%

EV / EBITDA (TTM)

32.46

Price / EBITDA (TTM)

36.41

Price / Free Cash Flow (TTM)

71.88

Book Value / Share

$134.54

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$10.11M

Total Cash

$3.58B

Debt to Equity

0.01

Issuance of Debt (TTM)

-$10.11M

Repayment of Debt (TTM)

-$10.11M

Key Statistics

Open

$1.02K

Close

$1.03K

Volume / Avg.

390.89K / 332.76K

Day Range

$1.01K - $1.04K

52 Wk Range

650.01 - 1.01K

Market Cap

$64.62B

P/E Ratio

37.83

Dividend Yield

-

Exchange

NASDAQ

RSI

73

Short Interest

2.13%

Days to Cover

4.71

About

Sector

Health Care

Industry

Biotechnology

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized mya...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS better than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS better than industry

FAQ

Q

How do I buy argenx (ARGX) stock?

A

You can purchase shares of argenx (NASDAQ:ARGX) through any online brokerage.

View our list of the best stock brokerages

Q

Who are argenx (ARGX) competitors?

A

Other companies in argenx’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for argenx (ARGX) stock?

A

argenx has a consensus price target of $1063.57.

Q

What is the current price for argenx (ARGX)?

A

The stock price for argenx (NASDAQ: ARGX) is $1032.86 last updated August 19, 2026 at 4:00 PM EDT.

Q

Does argenx (ARGX) pay a dividend?

A

There are no upcoming dividends for argenx.

Q

When is argenx (NASDAQ:ARGX) reporting earnings?

A

argenx does not have any upcoming earnings scheduled.

Q

Is argenx (ARGX) going to split?

A

There is no upcoming split for argenx.

Q

What sector and industry does argenx (ARGX) operate in?

A

argenx is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.